This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.86% per year. These returns cover a period from January 1, 1988 through February 2, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechnology: Archive
Catalyst Pharmaceuticals Q4 Earnings Beat, Firdapse Revenues Rise Y/Y
by Zacks Equity Research
CPRX tops Q4 estimates as Firdapse and Agamree sales jump, lifting 2025 results and driving upbeat 2026 revenue guidance.
CPRXNegative Net Change USNANegative Net Change CSTLNegative Net Change RXRXNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
After Golden Cross, CMS Energy (CMS)'s Technical Outlook is Bright
by Zacks Equity Research
Should investors be excited or worried when a stock's 50-day simple moving average crosses above the 200-day simple moving average?
CMSNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
ACAD Q4 Earnings Beat, Nuplazid & Daybue Drive Y/Y Revenue Growth
by Zacks Equity Research
Acadia beats Q4 EPS estimates as Nuplazid and Daybue lift revenues 9%, but sales miss and EU setback cloud trofinetide outlook with 2026 sales at $1.22-$1.28 billion.
USNANegative Net Change ACADNegative Net Change CSTLNegative Net Change RXRXNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
CYTK Posts a Wider-Than-Expected Q4 Loss, Advances Myqorzo Launch Plans
by Zacks Equity Research
CYTK reports a wider-than-expected Q4 loss as expenses rise, but Myqorzo wins FDA nod and global expansion advances, with $1.22B cash fueling 2026 catalysts.
SNYNegative Net Change BMYPositive Net Change BAYRYNegative Net Change CYTKNegative Net Change
biotechnology biotechs medical pharmaceuticals
RXRX Q4 Loss Narrower Than Expected, Revenues Increase Y/Y, Stock Up
by Zacks Equity Research
Recursion Pharmaceuticals stock up on narrower Q4 loss as revenues jump on Roche milestone, beating estimates and boosting cash runway into 2028.
CSTLNegative Net Change HRMYNegative Net Change IMCRNegative Net Change RXRXNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Apellis Q4 Loss Wider Than Expected, Revenues Decline Y/Y
by Zacks Equity Research
APLS posts wider-than-expected Q4 loss as Syfovre sales slip 8%, but revenues top estimates and Empaveli surges 50% on a strong new indication launch.
APLSNegative Net Change CSTLNegative Net Change HRMYNegative Net Change IMCRNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
GILD to Acquire ACLX for $7.8B & Gain Full Control of Anito-Cel
by Zacks Equity Research
Gilead is set to acquire Arcellx for $7.8B, gaining full control of anito-cel and boosting its cell therapy pipeline amid rising competition.
BMYPositive Net Change GILDPositive Net Change ACLXPositive Net Change
biotechnology biotechs cell-therapy medical pharmaceuticals
CRMD vs. TBPH: Which Small-Cap Biotech Stock Is the Better Bet?
by Ahan Chakraborty
CorMedix and Theravance take sharply different routes to small-cap biotech growth - one fueled by sales traction, the other by pipeline promise.
TBPHPositive Net Change CRMDNegative Net Change VTRSNegative Net Change
biotechnology biotechs medical pharmaceuticals
Royal Caribbean (RCL) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
RCLNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Telenor ASA (TELNY)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Should investors be excited or worried when a stock's 50-day simple moving average crosses above the 200-day simple moving average?
TELNYNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines